State Street Corp Buys 21,201 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)

State Street Corp boosted its stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 10.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 232,542 shares of the company’s stock after purchasing an additional 21,201 shares during the period. State Street Corp owned about 0.98% of Outlook Therapeutics worth $1,242,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in shares of Outlook Therapeutics in the 2nd quarter valued at $75,000. Christensen King & Associates Investment Services Inc. acquired a new position in Outlook Therapeutics in the 3rd quarter worth about $55,000. Squarepoint Ops LLC bought a new position in Outlook Therapeutics in the second quarter valued at about $232,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Outlook Therapeutics during the second quarter valued at about $303,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Outlook Therapeutics by 55.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after purchasing an additional 18,287 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Stock Performance

Outlook Therapeutics stock opened at $2.06 on Friday. The firm has a market cap of $51.31 million, a price-to-earnings ratio of -0.19 and a beta of 0.46. Outlook Therapeutics, Inc. has a 52-week low of $0.87 and a 52-week high of $12.85. The firm has a 50 day moving average price of $3.53 and a two-hundred day moving average price of $5.74.

Outlook Therapeutics (NASDAQ:OTLK) last announced its earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06. As a group, equities research analysts predict that Outlook Therapeutics, Inc. will post -3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on OTLK shares. BTIG Research dropped their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, November 29th. Finally, Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.73.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.